Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue

Pathology Research and Practice

Volumn 207, Issue 12, 2011, Pages 762-768

  Kwon, Mi Jung ^a   Lee, Seung Eun ^b   Kang, So Young ^b   Choi, Yoon La ^b  

^a Hallym University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

BRAF; Colorectal cancer; KRAS; Mutation; Peptide nucleic acids; PIK3CA

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; PARAFFIN; PEPTIDE NUCLEIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BRAF GENE; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVARY METASTASIS; PIK3CA GENE; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TISSUE FIXATION;

ADULT; AGED; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PARAFFIN EMBEDDING; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TRANSCRIPTION FACTORS;

EID: 82655177985     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.10.002     Document Type: Article

References (24)

1. Araki T., Shimizu K., Nakamura K., Nakamura T., Mitani Y., Obayashi K., Fujita Y., Kakegawa S., Miyamae Y., Kaira K., Ishidao T., Lezhava A., Hayashizaki Y., Takeyoshi I., Yamamoto K. Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. J. Mol. Diagn. 2010, 12:118-124.
2. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010, 16:790-799.
3. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer 2001, 37(Suppl. 4):S16-S22.
4. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
5. Choi J.J., Jang M., Kim J., Park H. Highly sensitive PNA array platform technology for single nucleotide mismatch discrimination. J. Microbiol. Biotechnol. 2010, 20:287-293.
6. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
7. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
8. Hyodo I., Suzuki H., Takahashi K., Saito Y., Tanaka S., Chiu H.M., Kim N.K., Li J., Lim R., Villalon A., Boku N. Present status and perspectives of colorectal cancer in Asia: Colorectal Cancer Working Group report in 30th Asia-Pacific Cancer Conference. Jpn. J. Clin. Oncol. 2010, 40(Suppl. 1):i38-i43.
9. Li J., Wang L., Mamon H., Kulke M.H., Berbeco R., Makrigiorgos G.M. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat. Med. 2008, 14:579-584.
10. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouche O., Landi B., Louvet C., Andre T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26:374-379.
11. Mancini I., Santucci C., Sestini R., Simi L., Pratesi N., Cianchi F., Valanzano R., Pinzani P., Orlando C. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J. Mol. Diagn. 2010, 12:705-711.
12. Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med. 2005, 352:476-487.
13. Neumann J., Zeindl-Eberhart E., Kirchner T., Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 2009, 205:858-862.
14. Nielsen P.E., Egholm M., Berg R.H., Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991, 254:1497-1500.
15. Oltedal S., Aasprong O.G., Moller J.H., Korner H., Gilje B., Tjensvoll K., Birkemeyer E.M., Heikkila R., Smaaland R., Nordgard O. Heterogeneous distribution of K-RAS mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int. J. Colorectal Dis. 2011, 26:1271-1277.
16. Orum H., Nielsen P.E., Egholm M., Berg R.H., Buchardt O., Stanley C. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 1993, 21:5332-5336.
17. Rizzo S., Bronte G., Fanale D., Corsini L., Silvestris N., Santini D., Gulotta G., Bazan V., Gebbia N., Fulfaro F., Russo A. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treat. Rev. 2010, 36(Suppl. 3):S56-S61.
18. Sartore-Bianchi A., Di Nicolantonio F., Nichelatti M., Molinari F., De Dosso S., Saletti P., Martini M., Cipani T., Marrapese G., Mazzucchelli L., Lamba S., Veronese S., Frattini M., Bardelli A., Siena S. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287.
19. Schubbert S., Shannon K., Bollag G. Hyperactive RAS in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
20. Thiede C., Bayerdorffer E., Blasczyk R., Wittig B., Neubauer A. Simple and sensitive detection of mutations in the RAS proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res. 1996, 24:983-984.
21. Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., Carneiro F., Oliveira C., Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
22. Weichert W., Schewe C., Lehmann A., Sers C., Denkert C., Budczies J., Stenzinger A., Joos H., Landt O., Heiser V., Rocken C., Dietel M. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J. Mol. Diagn. 2010, 12:35-42.
23. Wolpin B.M., Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310.
24. Zuo Z., Chen S.S., Chandra P.K., Galbincea J.M., Soape M., Doan S., Barkoh B.A., Koeppen H., Medeiros L.J., Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod. Pathol. 2009, 22:1023-1031.